MOLECULAR BIOMARKERS IN THE CLASSIFICATION OF GLIMOAS

本研究的目的是鉴定和评价分子标记。 对胶质瘤的分类和分级很有帮助。目标客户 选择《具体目标》中所列项目是为了解决 我们相信，肿瘤分类中的问题的解决将 显著改善患者的诊断和治疗 患有脑瘤。这些问题包括：(1)详细信息和诊断 毛囊型星形细胞瘤光谱分子变化的特异性 在神经纤维瘤病1患者和一般患者中均可发生 没有这种常见遗传易感性的人群 儿童肿瘤，(2)类似分子的存在或不存在 散发性非毛囊性肿瘤的改变(高级别纤维性 星形细胞瘤和少突胶质细胞瘤)以及它们之间的关系 对于肿瘤的分类，(3)较高级别的预后效用 星形细胞肿瘤细胞周期标志物Ki-67及其扩增 表皮生长因子受体基因，(4)基因组 纤维性星形细胞增生症与肿瘤进展相关的异常 和少突胶质细胞肿瘤，以及这些变化如何用于 肿瘤分级和预后；(5)肿瘤范围的确定 用明确的分子方法对未经治疗的胶质母细胞瘤进行分期。 拟议的研究受益于与 多中心中枢神经系统联盟脑肿瘤治疗的新方法(NABTT)。 NABTT将提供对稀有组织资源的便捷访问， 大量临床和科学数据来自一大批 我们的分析需要诊断为原发性胶质瘤的患者。我们的 从基于聚合酶链式反应的高效方法中得出的分子发现将 与临床参数相关，包括对特定疾病的反应 NABTT开始治疗。我们合作社之间的密切互动 神经胶质瘤网络多学科研究小组和NABTT将 大大扩展了这两项研究的资源。这些研究将 提高我们对这些肿瘤的分子变化的了解 提供可与预后相关的诊断标记物。 此外，这些数据将为今后对 脑胶质瘤的病理生理机制及其治疗的新途径 治疗。

The goals of this study are to identify and evaluate molecular markers useful in the classification and grading of gliomas. The intended projects, as listed in the Specific Aims, were selected so as to address problems in tumor classification whose resolution, we believe, will significantly improve the diagnosis, and therefore treatment, of patients with brain tumors. These issues include: (1) the details and diagnostic specificity of molecular changes in spectrum of pilocystic astrocytomas arising in both patients with neurofibromatosis 1 and in the general population without a recognized genetic predisposition to this common pediatric neoplasm, (2) the presence or absence of similar molecular changes in sporadic non-pilocystic tumors (high grade fibrillary astrocytic tumors and oligodendrogliomas) and how these might be related to tumor classification, (3) the prognostic utility in higher grade astrocytic neoplasms of the cycling cell marker Ki-67 and amplification of the epidermal growth factor receptor gene, (4) the genomic abnormalities associated with tumor progression in fibrillary astrocytic and oligodendroglial neoplasms, and how these changes can be used in tumor grading and prognosis, and (5) the determination of tumor extent (staging) of the untreated glioblastoma by unambiguous molecular methods. The proposed research benefits from strong interactions with the multicenter CNS Consortium New Approaches to Brain Tumor Therapy (NABTT). NABTT will provide ready access to rare tissue resources and the extensive clinical and scientific data from a large collection of patients diagnosed with primary gliomas required for our analyses. Our molecular findings derived from PCR-based highly efficient methods will be correlated with clinical parameters including the response to specific NABTT initiated treatments. Close interactions between our Cooperative Glioma Network multidisciplinary research team and the NABTT will significantly extend the resources of both studies. These studies will improve our knowledge of the molecular alterations of these tumors and provide diagnostic markers that can be correlated with outcome. Moreover, these data will provide the basis for future studies on the pathophysiologic mechanisms of gliomas and lead to new approaches to treatment.